Compare Firy Inc. (FIRY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Viatris Inc — how do they compare? Firy Inc. trades at $8.19 (market cap $125.48M), while Viatris Inc trades at $17.3 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 154.9× Firy Inc.'s market cap, and Viatris Inc pays a 2.88% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | VTRS | |
|---|---|---|
Market Cap | $125.48M | $19.44B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $17.39 |
52-Week Low | $2.28 | $8.74 |
Enterprise Value | $69.16M | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $8.39, up 4.35% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company recently rebranded from Skillz Inc. and reported Q1 2026 revenue growth but continues significant losses, with a net income margin of -57.48%. Cash flow remains negative, though operating losses have narrowed from prior years.
Outlook is mixed: technical momentum and revenue stabilization offer potential upside, but persistent losses, negative cash flow, and weak profitability metrics pose substantial risks. Analyst consensus is neutral with 60% hold ratings, reflecting cautious optimism amid ongoing financial challenges.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
